Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EQUR: SEC registration revoked:
https://www.sec.gov/files/litigation/opinions/2023/34-98688.pdf
EQUR SEC Admin. Proceeding for severely delinquent Financials:
https://www.sec.gov/litigation/admin/2023/34-97564.pdf
Will check it out asap.
Thanks.
“Our management believes that our operations will generate revenues in the US beginning of 2022. We expect that FDA approval for our BST Device will improve our ability to generate revenues from sales in other geographic areas.”
- from latest filing on 1/13/2022
That would be for their BST Device correct?
Any sources for real world data as to how effective it actually is?
Always looking for new and innovative med/biotech coming from microcaps.
"Minimal" capital invested with astronomical rewards if they hit the target.
TIA
“Our management believes that our operations will generate revenues in the US beginning of 2022. We expect that FDA approval for our BST Device will improve our ability to generate revenues from sales in other geographic areas.”
Source: 10-Q
There isn’t much recent info out there. Only the filings...
Where can I find more info on this stock?
Can be a winner but must read first
Well someone decided to throw $1,600 on this...
That’s a start!
Waiting for FDA approval
EQUR SECURITY DETAILS
Share Structure
Market Cap Market Cap
5,527,399
04/15/2020
Authorized Shares
500,000,000
04/15/2020
Outstanding Shares
34,546,243
04/15/2020
Restricted
21,065,321
04/15/2020
Unrestricted
13,480,922
04/15/2020
Held at DTC
4,934,921
04/15/2020
TAKE NOTICE HERE FOLKS!
Float
13,480,922
05/15/2019
....anyone else here or am I all alone in this one?
Are we on the Breakout Boards yet?
LOL
Looks like someone was loading at open... approx $20,000 worth up to 0.17...
I can't find any post anywhere. $ volume is big today. hope it comes
We got some volume... can it turn into something???
EQUR heading to 0.2+ bounce from this nice 8k today
Item 8.01 Other Events.
E-Qure Corp., a Delaware corporation (the “Company”), reported today that it has successfully completed its 2018 funding program in the total amount of $1.231 Million (the “2018 Funding Program”). The 2018 Funding Program included three stages, which included: (1) the successfully closing of its Subscription Rights Offering pursuant to a registration statement on Form S-1 (the “Registration Statement”); (2) the completion of the Company’s private Unit Offering pursuant to Regulation S (the “Reg S Unit Offering”; and (3) the conversion of debt to equity by its management team, all as discussed more fully below.
In June 2018, the Company received net proceeds of $532,147 from the Subscription Rights Offering pursuant to the Registration Statement that was declared effective under the Securities Act of 1933, as amended (the “Act”) by the SEC on May 10, 2018.
Following the second quarter ended June 30, 2018, the Company, pursuant to its Reg S Unit Offering, raised an additional $423,400 from the private sale of a total of 4,234,000 Units at $0.10 per Unit, each consisting of: (i) one share of Common Stock; (ii) one Class A Warrant exercisable for a period of 24 months to purchase ½ share of Common Stock at the equivalent of $0.50 per share; and (iii) one Callable Class B Warrant exercisable for a period of 36 months to purchase ½ share of Common Stock at the equivalent of $1.25 per share. The Reg S Unit Offering was made in an “offshore transaction” to 18 accredited, all of whom were non “U.S. Persons” as defined in Rule 902(h) promulgated by the SEC under the Act.
In addition, after the quarter ended June 30, 2018, the Company’s executive officers and chairman converted debt in the aggregate amount of $275,303 into units consisting of a total of: (i) 2,753,030 restricted shares, 1,376,515 Class A Warrants and Class B Warrants, having the same terms as the Class A and Class B Warrants set forth in the Reg S Unit Offering, and 2,750,000 Class C Warrants exercisable to purchase one share of Common Stock at a price of $1.00 per Share.
The Company intends to use the total equity capital raised under its Registration Statement and Reg S Unit Offering for general corporate purposes, including working capital and capital expenditures in furtherance of development and commercialization of its BST Device, a new and novel electrotherapy for the non-invasive treatment of hard-to-heal chronic wounds. The BST Device has received the Conformité Européenne (European Conformity -“CE”) mark and was approved to be sold in the EU market.
https://www.sec.gov/Archives/edgar/data/1563536/000149315218014603/form8-k.htm
Volume is still crappy here...
But it is building as of late.
0.08s are gone now... time for some great news soon...
#lotto
EQUR news out Electrical Stimulation Therapy and E-Qure - A Potential 20x in 18 Months or Less
https://www.accesswire.com/464162/Electrical-Stimulation-Therapy-and-E-Qure---A-Potential-20x-in-18-Months-or-Less%20.
The product is approved in Israel and the EU. It is shortly awaiting reimbursement in both areas. Comically, the device and procedure are reimbursed but not approved in the U.S.
The company is negotiating with distributors and expects to finalize a deal by the end of the third quarter for the U.S. market. The Israeli and EU launches, meanwhile, may have a significant impact on the share price.
The company is preparing to initiate their U.S.-based clinical study. The study will include 90 patients randomized to either BST or a sham device, meaning that this is not a long or complicated trial to run. The study will be complete within 12 to 15 months, but interest will build in front of this important catalyst.
OMG, somebody buying everything up to 23 cents and half an hour later somebody hitting 13's on the downside? Are you friggin kidding me? How stupid can one be?
Being patient with this one...
But we will need something to happen
EQUR looks like some flippers from last dip trying to take some tiny profit here. LOL idiots
I couldn't find anything new from my side. Good for bulls.
Hmmm... that's a good chunk of money... wonder if there's something behind it...
EQUR 0.23. someone took everything under 0.22 at one shot
OS is still 22,012,745 per OTC markets as of 3/29/17
m2m
Pretty quiet here lately...
Glen0 here with $EQUR
It is my opinion, that this very under the radar GEM has fallen RIGHT to the sweet spot for a potential MEGA run into dollars when DOTS start getting connected with the players involved here and the Israeli and FDA approvals.
Thie will not take long to catch on. It's very thin and that appeared to be released for potential liquidity as a dilutor was never pressing the box. By end of Friday it seemed all but done for now. Looks like we could move sharply if that's the case.
I will continue to monitor and release DD when we have more traction -
Love it ASK .33 now & thin
EQUR starting to roll out lots of good news
E-QURE's BST Device for Chronic Wound Care Receives Marketing Approval in Israel PR Newswire "Press Releases US - English"
NEW YORK , February 24, 2017 /PRNewswire/ --
From Rig's board, RIGATONI
Friday, 02/24/17 09:09:05 AM
Post # of 305348
~EQUR .28 with 2 pieces of news...
https://www.otcmarkets.com/stock/EQUR/news/U-S--FDA-Approves-Increase-in-Number-of-Clinical-Sites-for-E-QURE-rsquo-s-Pivotal-Trial-of-BST-Device-for-the-Treatment-of-Chronic-Wound-Care?id=151856&b=y
E-QURE's BST Device for Chronic Wound Care Receives Marketing Approval in Israel
https://www.otcmarkets.com/stock/EQUR/news/E-QURE-s-BST-Device-for-Chronic-Wound-Care-Receives-Marketing-Approval-in-Israel?id=151947&b=y
U.S. FDA Approves Increase in Number of Clinical Sites for E-QURE’s Pivotal Trial of BST Device for the Treatment of Chronic Wound Care
Me too. Picked a few shares.
$EQUR Twitter is active
#WoundCare: Huge Clinical and Economical Burden with yesterday's treatments. $EQUR 's BST is the future of wound care. pic.twitter.com/YnWOJbb4Hq
— E-QURE (@EQUR_IR) February 22, 2017
EQUR took a few more today...shld see a pr soon.
Thanks hdogtx, got it.
You didnt scroll down to the SEC filings part
Hi Hdogtx, the link you provided for the 8k takes me to an old filing from 2016. thanks
http://www.otcmarkets.com/stock/EQUR/news
http://www.otcmarkets.com/stock/EQUR/filings
Take a peek, per news and filings we have insiders buying in open market, FDA approval, Distribution agreements internationally... and 2nd Q 2017 uplist to NASDAQ....
Market Value $6,603,769
a/o Feb 21, 2017
Authorized Shares 500,000,000
a/o Sep 30, 2016
Outstanding Shares 22,012,562
a/o Nov 21, 2016
Float 4,700,354
a/o May 31, 2016
EQUR 8k
next Israeli OWCP/TECR type
On February 20, 2017 , E-Qure Corp. (the "Registrant") received the official certification from the Israeli Ministry of Health authorizing the use of the Registrant's BST Device in Israel . The BST Device implements patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure.
http://archive.fast-edgar.com/20170222/AOK2D22CZ22TD2Z2222Q22ZLOAKNGZ224292
Is she going higher tomorrow?
Such a beast!!!!
EQUR 0.26 X 0.326
You can try and contact the company . I can get you their info contact
Do you have an idea what peak sales would be?
Followers
|
18
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
949
|
Created
|
11/21/08
|
Type
|
Free
|
Moderators |
Centriforce, Inc. is a New Jersey corporation based in Florida with offices in Israel. It is dedicated to developing and delivering a new technology for the desalination of salt water into fresh, potable drinking water that can be used for irrigation or consumption.
The focus of the company is the development of a new vacuum force desalination technology that we believe will revolutionize the desalination industry by allowing for the desalination of sea water at lower costs. We believe our technology will require far less energy input than current technologies require. The company has financing on hand to complete the construction of its initial prototype desalination plant which it expects to complete in 2008.
In 2008, the company acquired Ocean Transformation Technologies, Ltd. and Israeli company engaged in the development of desalination technology.
Centriforce's technology is designed to use less energy to purify salt water than current reverse-osmosis and flash distillation technologies. By reducing energy input requirements, the Company can reduce the cost of producing fresh water and make it more widely available to regions of the world where shortages occur.
"The scarcity of water and the extraordinary profits that can be made may overwhelm ordinary public sensibilities." - Business Week, 6/2008
"Governments had been slow to accept the awful truth that usable water is running out." - Lord Stern, World Bank former Chief Economist
The demand for fresh water pushed by worldwide shortages is pushing the development of new desalination technologies. Nations like Israel are leading the challenge with the help of
companies like General Electric, [NYSE:GE] and Dow Chemical, [NYSE:DOW].
The two most common technologies used to purify water are flash distillation and reverse-osmosis. Flash distillation involves evaporating salt water in a low-pressure vessel and then distilling the potable water out of the fluid mix. The system is efficient but expensive because it requires a high degree of energy input to evaporate the water.
Reverse osmosis is used by most large plants in service today. With this system the salt water is pumped under pressure through a series of filters with pores small enough to let the water molecules pass through the membrane while trapping salt and other minerals. Reverse osmosis is costly because of the energy consumed by the pressure pumps and the cost of filters which must regularly be replaced. In addition, reverse osmosis creates a strong liquid salt brine which is an environmentally negative waste product.
Centriforce is developing a technology platform that we believe will require less energy input that current technologies. Our system is designed to maximize the physics of force differential in a wind column allowing for the evaporation of the salt water with no heat input. After the water is evaporated it will be separated from the minerals and salts using existing separation technology.
The waste product of this process will be dry salts and minerals which will be much easier to dispose of or commercialize than the waste products of reverse osmosis. Most importantly, we expect this technology to require much lower energy input and, therefore, produce potable water at a lower cost than competing technologies.
Centriforce Technology Corp.
Waterford Business Park
5201 Blue Lagoon Drive
Suite 800
Miami, FL 33126
Phone: (305) 718-3330
Fax: (206) 666-2009
Email: info@cnfowater.com
Estimated Market Cap
$19,129,593 as of Feb 6, 2009
Outstanding Shares
23,616,782 as of Dec 31, 2008
Authorized Shares
50,000,000 as of Dec 31, 2008
Float
5,054,837 as of Dec 31, 2008
Recent News | |||
Date |
| ||
03/17/2009 | Centriforce to Meet World Water Leaders in Istanbul | ||
02/05/2009 | CNFO To Bid on Navy Contracts | ||
01/29/2009 | CNFO Expands Technology to Clean Water From Tar Sands | ||
01/22/2009 | Centriforce Joins The World Water Council | ||
01/20/2009 | Centriforce Technology Successfully Tests Technology | ||
01/09/2009 | Centriforce To Unveil New Desalination Technology At ‘World Water Forum 5’ in Istanbul | ||
12/15/2008 | Centriforce: Why Water and The Thirst for Profits | ||
12/01/2008 | Centriforce Technology's Desalination Process Will Reduce Energy Requirements with Lower Environmental Impact | ||
11/17/2008 | Centriforce Technology Advancement |
Mr. Schulman, 52, has an extensive engineering background in refining, petrochemical and separation technologies. He has served as President of Sentinel Telecom, Inc. in Miami, Florida since 2002 and as President of Wireless Networks International, Inc. (WNI) in Miami, Florida from 1996 to 2002. He also served as VP International Marketing for WorldNet Fiber, Inc., where he was responsible for project development, business strategies, regulatory issues, partner development and international marketing. He was also responsible for network design, engineering, procurement and installation of worldwide telecommunications facilities and satellite teleports. He studied chemical engineering from 1974 to 1978 at Rensselaer Polytechnic Institute, Troy, NY.
Steven M. Plumb, CPA has recently joined as the Company's Chief Financial Officer. Mr. Plumb has over 25 years of experience in accounting and consulting in the technology, health care, and biotech industries. From July 2001 to the present, Mr. Plumb has served as the president of Clear Financial Solutions, Inc. a business consulting firm, which he founded in 2001, that assists public and private companies with financing, operations improvement, outsourced accounting, SEC reporting, mergers and acquisitions, and financial analysis. From October 2005 to the present, Mr. Plumb has also served as the Chief Financial Officer of HoustonPharma, Inc. of which he was a co-founder. From 2002 through 2004, Mr. Plumb served as Vice President and Chief Financial Officer of Adventrx Pharmaceuticals, Inc. During his tenure as CFO of Adventrx, the company raised in excess of twenty million dollars and progressed from the Over-the-Counter Bulletin Board to listing on the American Stock Exchange. Prior to this, Mr. Plumb served as the Chief Financial Officer of DePelchin Children's Center, and as controller of Memorial City Rehabilitation Hospital in Bellaire, Texas. Mr. Plumb is a former auditor and consultant with KPMG. Mr. Plumb earned his BBA degree in accounting from the University of Texas at Austin.
Mr. Silber, 45, is a member of the management team of Qabx S.A. a distribution company dealing with the import and export of retail products in the United States. Qabx was founded in 2003. From 1999 to 2003, he was a member of the management team of Abraxas-International, a manufacturer and distributor of jewelry in the United States. He studied business management at the University of Houston and is fluent in English, Spanish and Hebrew.
Mr. Goldenberg, 48, is a business owner in Israel. He is the founder and owner of a chain of optometry offices in Israel since 1988. He is also the founder and owner of a software company Digital Horizon, Ltd., providing management software to optometrists. He is a graduate of the Pennsylvania College of Optometry with a B.S.c. degree. He also holds a M.S.c. degree in clinical optometry from PCO. He holds a diploma in optometry from Bar Ilan University in Tel Aviv.
"Israel's water economy is on the brink of a crisis," reports the Israel ministry of foreign affairs. Demand and consumption are increasing, exceeding the capacity of the natural resources, which are being depleted. Water quality in the sources is deteriorating, due to over-exploitation and intensive human activity.
Centriforce has its roots in the acquisition of Ocean Transformation Technologies, an Israeli corporation developing a new, low energy, desalination technology. As a result, the heart of our business focus is to address the water needs of Israel. Water becomes a security issues much has oil has worldwide when supply falls below the levels needed to sustain the activities of the nation's population.
We are dedicated to increasing Israel's security by increasing its access to this critical commodity using our new technology.
The Ministry of National Infrastructure in Israel has decided to, "increase considerably the supply of potable water, mainly through seawater desalination and purification of water sources." See, www.israel-mfa.gov.
Water is a scarce commodity in Israel. The country is situated in an arid zone and the natural resources are insufficient to meet the ever-rising demand. The necessity to use water in a rationing regime was first enacted in the 1950's Water Law. The Water Law did away with private ownership of water resources [infrastructure such as desalination plants can be privately owned, however] and established an allocation mechanism for water that has earned the respect of nations around the world.
Israel's Water Law is based on the following principals:
Desalination processes enable the nation to produce water from saline and/or contaminated raw water sources. In the past few years, the Israel Water Commission initiated and supported, on a large scale, three types of desalination projects to generate new water supply sources.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |